Recombinant CD274 (Avelumab Biosimilar) anticorps

N° du produit ABIN7200665

Cet anticorps Humanized Monoclonal détecte spécifiquement CD274 (Avelumab Biosimilar) dans FACS et in vivo. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Recombinant CD274 (Avelumab Biosimilar) anticorps (ABIN7200665)

Antigène: CD274 (Avelumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp CD274 (Avelumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-CD274 (Avelumab Biosimilar) anticorps

Fonction: Avelumab Biosimilar, Human PD-L1 Monoclonal Antibody

Specificité: The in vivo grade avelumab biosimilar specifically binds to the programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and B7-1.

Attributs du produit: What is Avelumab biosimilar research grade? Avelumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1 (B7-H1 or CD274, programmed cell death ligand 1), with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab is used for the treatment of several kinds of carcinoma. Avelumab biosimilar uses the same protein sequences as the therapeutic antibody of Avelumab. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Avelumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body's adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: The anti-human PD-L1 monoclonal antibody avelumab biosimilar was produced in the avelumab biosimilar Chinese Hamster Ovary (CHO) stable cell line.

Isotype: IgG1

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by avelumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Stock: 4°C,-20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur CD274 (Avelumab Biosimilar)

Antigène: CD274 (Avelumab Biosimilar)

Autre désignation: Avelumab Biosimilar

Classe de substances: Biosimilar